Some batches of Durisan hand sanitizer have been previously recalled and in a new update, the company has further expanded the recall. The U.S. Food and Drug Administration (FDA) explained that the move was due to the fact that the affected hand sanitizers were contaminated with a type of bacteria that could infect the users.
The expanded recall announcement
Based on the FDA’s recall notice that was posted on Tuesday, May 18, Durisan Sanit Technologies updated the recall for its anti-microbial hand sanitizer products. Now, the batches of products to be recalled were expanded to add those that were manufactured after April 10, 2019, and have not expired yet.
The company made the decision because the affected bottles were said to have been contaminated with common bacteria called Burkholderia contaminans. People infected may not experience reactions but for others, they may suffer from more serious effects once the bacteria enter their bloodstream through scrapes or wounds after using the hand sanitizer.
An infection could result from this, as per the FDA. The agency also warned that people with weaker immune systems are more susceptible to infection so the use of the contaminated hand sanitizer is risky.
Other information of the recalled lots
Fox Business mentioned that as per the Centers for Disease Control and Prevention (CDC), Burkholderia cepacia is found in water and soil. This bacteria may also be a little complicated to treat because it is said to be usually resistant to common antibiotics.
In any case, the recalled Durisan hand sanitizer includes 47 lots of the products. These covered the ones packed in various bottle sizes of 18 ml credit cards, 118 ml, 236 ml, 300 ml and 500 ml. The wall-mounted dispensers that use 1000 ml bottles are also included.
Fortunately, there is no report of adverse reactions yet or complaints from customers regarding the contaminated Durisan hand sanitizer. With the voluntary recall of its maker, the FDA said that distributors and retailers were already notified too.
“Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using this drug product,” the FDA wrote in the expanded recall announcement. “Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.”


Oil Prices Extend Four-Day Rally as U.S.-Iran Conflict and Red Sea Threats Raise Supply Fears
Cathay Pacific Sees H1 Profit Surge on Strong Travel Demand
US Stock Futures Steady Ahead of Tesla, Alphabet Earnings as Iran Conflict Keeps Markets on Edge
Saudi Oil Tankers Reverse Course as Houthi Threats Disrupt Red Sea Shipping
Wistron Opens $700M Texas AI Factory to Build Nvidia Superchips in U.S.
Asian Stocks Rise as Oil Retreats on Iran Ceasefire Hopes Ahead of Key AI Earnings
South Korea Q2 GDP Beats Forecasts as AI Chip Exports Drive Growth
Judge Approves Anthropic’s $1.5 Billion AI Copyright Settlement With Authors
Ryanair Warns Summer Airfares May Stay Lower as Quarterly Profit Misses Estimates
Nasdaq Drops as AI Earnings, Oil Surge and Middle East Tensions Weigh on Wall Street
Japan PM Sanae Takaichi Unveils Growth Plan as BOJ Independence Concerns Lift Bond Yields
Gold Price Climbs Above $4,130 as Middle East Tensions Boost Safe-Haven Demand
OpenAI Australia Data Center Switches Cooling Strategy After Recycled Water Plan Fails
GM Q2 Earnings Beat Estimates as General Motors Raises 2026 Profit Outlook
Super Micro Computer Stock Jumps 20% After Record AI Orders and Margin Surge
Australia ASIC Tightens Auditor Oversight After KPMG Leak Scandal
Trump Set to Unveil New Tariffs on Dozens of Countries as Global 10% Duty Nears Expiration 



